Sviatoslav Chekhun

🧬 Liquid Biopsy in Clinical Practice: Past, Present & Future🩸 A new review explores the evolution, applications, and future directions of liquid biopsy in oncology. Here are the key insights: 🔬Technologies & Biomarkers ✅ Circulating Tumor Cells (CTCs) – Enrichment & detection methods (PCR, IHC, FISH, scRNA-seq) ✅ Circulating Tumor DNA (ctDNA) – PCR & NGS-based detection for genomic alterations ✅ Exosomes – Advanced methods for isolating tumor-derived extracellular vesicles 📊Clinical Applications ✅ Early Cancer Detection– Liquid biopsy enhances non-invasive screening ✅ Cancer Staging & Prognosis– Stratifies patients based on risk & molecular profiling ✅ Therapy Guidance – Detects actionable mutations like ESR1, PIK3CA, EGFR, ALK for precision medicine ✅ Treatment Response Monitoring – Tracks minimal residual disease (MRD) & therapy resistance 🚀Advancing Liquid Biopsy for Multi-Cancer Screening ✅ Emerging multi-cancer detection technologies: CCGA3, CancerSEEK, THUNDER, DETECT-A, PATHFINDER ✅ AI & machine learning integration for enhanced diagnostic accuracy 🔮Future Directions ✅ Standardization & Validation – Steps to clinical utility ✅ Multi-Omics Approach – Integrating genomics, transcriptomics, and proteomics ✅ Ex Vivo Models – Using CDX mouse models for precision therapy testing 🌍Liquid biopsy is revolutionizing oncology—enhancing early detection, personalized treatment & real-time monitoring. 🔗 Read the full study: doi.org/10.1016/j.critrevonc… @DrYukselUrun @ChristianRolfo @ElJanLe @UmbertoMalapel1 @oncodaily @ErulEnes @drgandara @MJOSESERRANO19 @CHematology @Elsevier_Med #LiquidBiopsy #PrecisionOncology #ctDNA #CancerDetection #ISLB 🚀